249 related articles for article (PubMed ID: 38459552)
1. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
Hofmeyr GJ; Singata-Madliki M; Batting J; Balakrishna Y; Morroni C
BMC Womens Health; 2024 Mar; 24(1):167. PubMed ID: 38459552
[TBL] [Abstract][Full Text] [Related]
2. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
3. Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial.
Ryan R; Mussa A; Singtaa-Madliki M; Batting J; Balakrishna Y; Morroni C; Hofmeyr GJ
Front Glob Womens Health; 2022; 3():887541. PubMed ID: 35669313
[TBL] [Abstract][Full Text] [Related]
4. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
Hofmeyr GJ; Singata-Madliki M; Batting J; Steyn P; Thomas KK; Issema R; Beesham I; Mbatsane E; Morrison C; Deese J; Smit J; Philip N; Palanee-Phillips T; Reddy K; Onono M; Mastro TD; Baeten JM;
PLoS One; 2024; 19(5):e0299802. PubMed ID: 38722832
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
[TBL] [Abstract][Full Text] [Related]
6. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
Morrison CS; Hofmeyr GJ; Thomas KK; Rees H; Philip N; Palanee-Phillips T; Nanda K; Nair G; Onono M; Mastro TD; Lind M; Heffron R; Edward V; Deese J; Beksinska M; Beesham I; Stringer JSA; Baeten JM; Ahmed K;
AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
[TBL] [Abstract][Full Text] [Related]
7. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
Beesham I; Bosman S; Beksinska M; Scoville CW; Smit J; Nanda K
Contraception; 2022 Apr; 108():37-43. PubMed ID: 34848180
[TBL] [Abstract][Full Text] [Related]
8. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.
Beksinska M; Issema R; Beesham I; Lalbahadur T; Thomas K; Morrison C; Hofmeyr GJ; Steyn PS; Mugo N; Palanee-Phillips T; Ahmed K; Nair G; Baeten JM; Smit J
EClinicalMedicine; 2021 Apr; 34():100800. PubMed ID: 33898953
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
Mugo NR; Stalter RM; Heffron R; Rees H; Scoville CW; Morrison C; Kourtis AP; Bukusi E; Beksinka M; Philip NM; Beesham I; Deese J; Edward V; Donnell D; Baeten JM;
Clin Infect Dis; 2022 Sep; 75(4):586-595. PubMed ID: 34910143
[TBL] [Abstract][Full Text] [Related]
10. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.
Tanko RF; Bunjun R; Dabee S; Jaumdally SZ; Onono M; Nair G; Palanee-Phillips T; Harryparsad R; Happel AU; Gamieldien H; Qumbelo Y; Sinkala M; Scoville CW; Heller K; Baeten JM; Bosinger SE; Burgener A; Heffron R; Jaspan HB; Passmore JAS
J Infect Dis; 2022 Sep; 226(5):907-919. PubMed ID: 35263421
[TBL] [Abstract][Full Text] [Related]
12. Weight change at 12 months in users of three progestin-only contraceptive methods.
Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
[TBL] [Abstract][Full Text] [Related]
13. Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.
Deese J; Chen PL; Gao X; Heffron R; Hobbs M; Lapple D; Jaspan H; Miller A; Nair G; Onono M; Palanee-Phillips T; Reddy K; Steiner MJ
AIDS Behav; 2023 Mar; 27(3):978-983. PubMed ID: 36357806
[TBL] [Abstract][Full Text] [Related]
14. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
[TBL] [Abstract][Full Text] [Related]
15. Effects of three contraceptive methods on depression and sexual function: An ancillary study of the ECHO randomized trial.
Singata-Madliki M; Carayon-Lefebvre d'Hellencourt F; Lawrie TA; Balakrishna Y; Hofmeyr GJ
Int J Gynaecol Obstet; 2021 Aug; 154(2):256-262. PubMed ID: 33448029
[TBL] [Abstract][Full Text] [Related]
16. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
17. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
[TBL] [Abstract][Full Text] [Related]
18. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
Todd CS; Jones HE; Langwenya N; Hoover DR; Chen PL; Petro G; Myer L
PLoS Med; 2020 May; 17(5):e1003110. PubMed ID: 32442189
[TBL] [Abstract][Full Text] [Related]
19. Effect of low-dose oral contraceptives on androgenic markers and acne.
Thorneycroft IH; Stanczyk FZ; Bradshaw KD; Ballagh SA; Nichols M; Weber ME
Contraception; 1999 Nov; 60(5):255-62. PubMed ID: 10717776
[TBL] [Abstract][Full Text] [Related]
20. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
